These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3624100)

  • 21. FDA's conduct, review, and evaluation of inspections of clinical investigators.
    Turner G; Lisook AB; Delman DP
    Drug Inf J; 1987; 21(2):117-25. PubMed ID: 10282112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.
    Holbein ME
    J Investig Med; 2009 Aug; 57(6):688-94. PubMed ID: 19602987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.
    Berro M; Burnett BK; Fromell GJ; Hartman KA; Rubinstein EP; Schuff KG; Speicher LA;
    Acad Med; 2011 Feb; 86(2):217-23. PubMed ID: 21169787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procedures for emergency or treatment use of investigational drugs.
    Klecker RJ; Cipolle RJ
    Am J Hosp Pharm; 1987 May; 44(5):1086-9. PubMed ID: 3605118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Financial disclosure by clinical investigators--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(21):5233-54. PubMed ID: 10177332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of FDA regulations on the cochlear implant field.
    Sauberman HR
    Ann N Y Acad Sci; 1983; 405():451-7. PubMed ID: 6575667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of clinical trials for new drugs in animals.
    Muser RK
    J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1148-50. PubMed ID: 7216890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company.
    Beran RG
    Med Law; 2004; 23(4):913-24. PubMed ID: 15685926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment needs in HIV prevention trials: using beneficence to clarify sponsor-investigator responsibilities.
    Stobie M; Slack C
    Dev World Bioeth; 2010 Dec; 10(3):150-7. PubMed ID: 20002648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical trial primer: historical perspective and modern implementation.
    Karsh LI
    Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?
    Glass HE
    Dis Manag; 2004; 7(1):77-87. PubMed ID: 15035835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing oncology research protocols.
    Lunik MC
    Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishing value through pharmacoeconomics: the emerging third objective in clinical trials.
    Boyer JG; Pathak DS
    Top Hosp Pharm Manage; 1994 Jan; 13(4):1-10. PubMed ID: 10130679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Good clinical practices. Point of view of the university hospital].
    Bader JP
    Rev Med Interne; 1986 Nov; Spec No():11-3. PubMed ID: 3809775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory aspects of investigational new drugs.
    Arbit HM
    Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
    Englev E; Petersen KP
    Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.
    Herfarth HH; Jackson S; Schliebe BG; Martin C; Ivanova A; Anton K; Sandler RS; Long MD; Isaacs KL; Osterman MT; Sands BE; Higgins PD; Lewis JD
    Inflamm Bowel Dis; 2017 Jan; 23(1):14-22. PubMed ID: 27598744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
    Romano CA; Nair S; Delphin ES
    Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.